Takeda Pharmaceutical’s FY2026 financial results are projected to be approximately JPY 4.5 trillion in sales and JPY 1.66 trillion in net income, showing an increase compared to the same period last year. Adjustments for litigation reserves and business restructuring expenses are also reflected.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-06-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4502-20260605-01.pdf","jir_short_summary":"Takeda Pharmaceutical's FY2026 financial results are projected to be approximately JPY 4.5 trillion in sales and JPY 1.66 trillion in net income, showing an increase compared to the same period last year. Adjustments for litigation reserves and business restructuring expenses are also reflected.","jir_summary":"### Performance Overview\nTakeda Pharmaceutical's FY2026 financial results are expected to be approximately JPY 4.5 trillion in sales and JPY 1.66 trillion in net income, representing an increase from the same period last year. Despite adjustments for litigation reserves and restructuring expenses, the company maintains steady growth. Revenue has increased driven by strong sales of new and existing products, and net income has improved significantly. Considering potential litigation risks and currency fluctuations, the company aims for stable growth based on its long-term strategic plan.\n\n### Future Outlook and Impact on Shareholders\nTakeda Pharmaceutical anticipates continued growth in sales and profits in FY2026, promoting R&D and new drug launches while managing litigation risks and business restructuring costs. The company plans to increase dividends by JPY 204 per share, emphasizing shareholder returns. While remaining cautious of currency risks and regulatory changes, Takeda will continue its strategy focused on long-term growth and value enhancement.","jir_financial_highlights":"Sales Revenue: JPY 4.64 trillion (YoY +3.0%)\nNet Income Attributable to Owners of Parent: JPY 1.006 trillion (YoY +318.4 billion yen)\nTotal Sales: JPY 4.5057 trillion (YoY -1.7%)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #FinancialResults, #JapanStocks","jir_key_figures":"Sales Revenue: JPY 4.64 trillion (YoY +3.0%)\nNet Income Attributable to Owners of Parent: JPY 1.006 trillion (YoY +318.4 billion yen)\nDividend Forecast: JPY 204 (planned increase)","jir_meta_title":"[Takeda Pharmaceutical] Fiscal Year 2026 Financial Results | Sales JPY 4.6 trillion, Net Profit JPY 1.66 trillion","jir_meta_description":"Takeda Pharmaceutical's FY2026 financial results are projected to be approximately JPY 4.5 trillion in sales and JPY 1.66 trillion in net income, reflecting growth and including adjustments for litigation risks and restructuring costs. Dividends are also scheduled to increase.","jir_og_title":"[Takeda Pharmaceutical] Fiscal Year 2026 Financial Results | Sales JPY 4.6 trillion, Net Profit JPY 1.66 trillion","jir_og_description":"Takeda Pharmaceutical's FY2026 results forecast sales growth and net income expansion. The outlook considers litigation and currency risks while aiming for long-term growth.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-61793","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n